FTC Extends Waiting Period for LENSAR Merger

LENSAR ( (LNSR) ) just unveiled an update.

On March 23, 2025, LENSAR, Inc. entered into a merger agreement with Alcon Research, LLC, and its subsidiary, VMI Option Merger Sub, Inc., to become a wholly owned subsidiary of Alcon. However, on May 21, 2025, the Federal Trade Commission requested additional information, extending the waiting period for the merger under the Hart-Scott-Rodino Antitrust Improvements Act. LENSAR and Alcon plan to cooperate with the FTC, aiming to complete the merger in the second half of 2025, pending regulatory approval and other conditions.

The most recent analyst rating on (LNSR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.

Spark’s Take on LNSR Stock

According to Spark, TipRanks’ AI Analyst, LNSR is a Neutral.

LENSAR’s overall score is primarily influenced by its financial challenges, including ongoing losses and negative equity. However, strong revenue growth and a promising merger with Alcon provide potential for future improvement. Technical indicators suggest stable momentum, while valuation remains limited by negative earnings. The earnings call and merger news contribute positively but are offset by the financial issues.

To see Spark’s full report on LNSR stock, click here.

More about LENSAR

LENSAR, Inc. operates in the medical technology industry, primarily focusing on advanced laser systems for cataract surgery.

Average Trading Volume: 182,022

Technical Sentiment Signal: Buy

Current Market Cap: $166.4M

See more data about LNSR stock on TipRanks’ Stock Analysis page.